Karolinska Development company Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center
(Thomson Reuters ONE) -
STOCKHOLM - March 22, 2017. Karolinska Development's portfolio company Aprea
Therapeutics, a privately held, clinical stage biopharmaceutical company
developing novel anticancer therapies targeting the tumor suppressor protein
p53, today announced a collaboration with Memorial Sloan Kettering Cancer Center
to study the effects of reactivation of tumor suppressor protein p53 by APR-
246.
Details from the Aprea Therapeutics press release follow:
The goal of the collaboration is to evaluate and characterize preclinical
efficacy of APR-246 in combination with multiple other anti-cancer agents and
across multiple tumor types. The Principal Investigator of the study is Taha
Merghoub, Ph.D., and he will be conducting the research in collaboration with
the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and
Immunotherapeutics Service, Department of Medicine.
"We are excited to initiate this new collaboration with Memorial Sloan
Kettering," said Christian S. Schade, President and Chief Executive Officer of
Aprea Therapeutics AB. "These studies will not only provide important insight
into the effects of APR-246-induced p53 reactivation but also inform the
rationale for novel combination therapies to be tested in future clinical
trials."
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden(at)karolinskadevelopment.com
Viktor Drvota, Deputy CEO and Chief Investment Officer, Karolinska Development
AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota(at)karolinskadevelopment.com
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev(at)citigatedr.co.uk
TO THE EDITORS
About Aprea Therapeutics AB
Aprea Therapeutics AB is a Boston, Massachusetts- and Stockholm, Sweden-based
biopharmaceutical company focused on the discovery and development of novel
anticancer compounds reactivating the tumor suppressor protein, p53. The
Company's lead program, APR-246, a first-in-class small molecule drug candidate,
is in Phase II clinical development in ovarian cancer patients, and additional
clinical studies with APR-246 in other cancer indications are planned. In March
2016, Aprea completed a EUR 46 million Series B financing with an international
syndicate co-led by Versant Ventures and 5AM Ventures, with additional
participation by Sectoral Asset Management, HealthCap, acting as local lead
investor, and existing investor, Karolinska Development. For more information,
please visit www.apreatherapeutics.com.
About p53 and APR-246
The p53 tumor suppressor gene is the most frequently mutated gene in human
cancer, occurring in approximately 50% of all human tumors. These mutations are
often associated with resistance to anticancer drugs and poor overall survival,
representing a major unmet medical need in the treatment of cancer.
APR-246 has been shown to reactivate mutant p53 protein - by reconverting mutant
p53 into wild-type p53 conformation and function - and thereby induce programmed
cell death in human cancer cells. APR- 246 has demonstrated compelling pre-
clinical antitumor activity in a wide variety of solid and hematological (blood)
tumors, including ovarian cancer, small cell lung cancer, esophageal cancer and
AML (acute myeloid leukemia), among others. Additionally, strong synergy has
been seen with both traditional anticancer agents, such as chemotherapy, as well
as newer mechanism-based anticancer drugs and immuno-oncology checkpoint
inhibitors. In addition to pre-clinical testing, Phase I clinical studies with
APR-246 have been completed, demonstrating a favorable safety profile and both
biological and clinical responses in hematological malignancies and solid tumors
with mutations in the p53 gene. The Company has commenced a Phase II study on
ovarian cancer and is expecting to initiate additional clinical studies of APR-
246 in other cancer indications.
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make a
difference to patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes in
the Nordic region. The Company aims to build companies around scientists who are
leaders in their fields, supported by experienced management teams and advisers,
and co-funded by specialist international investors, to provide the greatest
chance of success.
Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a
proven track record as company builders and with access to a strong global
network.
For more information, please visit www.karolinskadevelopment.com
KD Aprea MSK (ENG):
http://hugin.info/143071/R/2089691/788954.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 531832
Anzahl Zeichen: 6553
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 159 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Karolinska Development company Aprea Therapeutics Announces Research Collaboration with Memorial Sloan Kettering Cancer Center"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
